Surveying the prevalence of multi-drug resistant organisms (MDROs) is crucial in determining an appropriate treatment plan for infections caused by these pathogens. Treating MDRO infections requires a multifaceted approach, as these organisms have become resistant to multiple classes of antibiotics. The patient's clinical status and risk factors should be evaluated to determine if hospitalization and aggressive therapies such as intravenous antibiotics are necessary. Additionally, infection control measures must be implemented to prevent transmission among patients and healthcare workers. Utilizing laboratory testing and molecular diagnostics can aid in identifying the specific MDRO causing the infection and guide targeted therapy options when available. In some cases, alternative treatments such as bacteriophages or immunotherapy may also be considered. It is essential that clinicians remain vigilant in monitoring for MDROs through ongoing surveillance programs to quickly identify outbreaks or rising resistance trends within their institution or community.
1.
Video: Liver transplant for patients with advanced colorectal cancer
2.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
3.
Blood tests can predict the risk of relapse after a bone marrow transplant in patients with acute myeloid leukemia.
4.
AI is useful in low-resource areas for triaging breast masses.
5.
Does pollution cause cancer?
1.
Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review
2.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
3.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
4.
Unlocking the Potential of Onivyde: A New Hope for Cancer Treatment
5.
Beyond the Cure: The Emerging Role of Tissue-Agnostic Therapies in Palliative Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
4.
Navigating the Complexities of Ph Negative ALL - Part VII
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation